Republican 2022 midterms underperformance is not expected to dampen Congressional Pharmacy Benefit Manager PBM reform. Issue remains at forefront of healthcare pricing debate. No longer seen as Republican-driven effort due to Inflation Reduction Act IRA drug pricing reforms.
The 2022 midterms have concluded, but the Republican underperformance is not expected to dampen Congressional enthusiasm for Pharmacy Benefit Manager (PBM) reform. The issue remains at.